Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
All content for Breast Cancer Conversations is the property of SurvivingBreastCancer.org and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
272. This AI Is Changing How We Treat Cancer—Personalized Medicine Explained
Breast Cancer Conversations
32 minutes
4 weeks ago
272. This AI Is Changing How We Treat Cancer—Personalized Medicine Explained
Love the episode? Send us a text! What if your cancer treatment was designed just for you? In this episode of Breast Cancer Conversations, host Dr. Laura Carfang sits down with Jim Foote, CEO and co-founder of First Ascent Biomedical, to explore how AI-powered functional precision medicine is transforming cancer care. Instead of relying on one-size-fits-all treatment plans, this breakthrough approach tests your actual tumor cells against hundreds of FDA-approved drugs—revealing which therapie...
Breast Cancer Conversations
Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
